In our clinical trial of 675 patients, Serenity’s underlying liquid biopsy technology was proven to help detect cancer signals that would not be discovered through standard screening. The cancers studied were: breast, bladder, liver, lung, prostate, pancreatic, and colorectal cancer. Our technology is proven to outperform other publicly available platforms on technical detection capabilities, detecting over 3,000 cancer-related locations with single-molecule precision.